We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pediatrix Ties Up to Provide Better Maternal Care in Tennessee
Read MoreHide Full Article
Key Takeaways
MD partnered with Tennessee Maternal-Fetal Medicine to expand high-risk pregnancy care in Nashville.
The acquired group adds five locations and specialized clinicians, enhancing maternal-fetal capabilities.
The cash deal is immediately accretive, expected to boost patient volumes and revenue growth.
Pediatrix Medical Group, Inc. (MD - Free Report) recently teamed up with Tennessee Maternal-Fetal Medicine, a specialist group focused on high-risk pregnancies and serving patients across five locations in the Greater Nashville area. The move is aimed at expanding the maternal health services suite of MD.
Following the deal, the practice will operate as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix network.
The transaction was completed in cash and is expected to be immediately accretive to Pediatrix’s bottom line. Financial details of the transaction were kept under wraps.
The addition of new providers and clinics is expected to drive higher patient volumes and support revenue growth for MD. Its same-unit net revenue increased 4% year over year in the fourth quarter of 2025. The expansion is likely to enhance its footprint in Tennessee, supporting stronger referral networks and more consistent patient inflow.
Such targeted expansions are expected to enable MD to capture the demand for specialized maternal care. Powered by four board-certified physicians along with six practice providers, Tennessee Maternal-Fetal Medicine seems to be an apt partner to complement MD’s endeavor, as the former’s professionals focus on complex pregnancies that require specialized monitoring and treatment.
MD’s Stock Price Performance
Shares of Pediatrix have gained 48.2% over the past year against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
MD’s Zacks Rank & Key Picks
Pediatrix currently carries a Zacks Rank #3 (Hold).
The Zacks Consensus Estimate for InnovAge Holding’s 2026 earnings is pegged at 25 cents per share, which has remained stable in the past 30 days. INNV beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 87.5%. The consensus estimate for 2026 revenues is pinned at $944.5 million, implying 10.6% year-over-year growth.
The Zacks Consensus Estimate for PACS Group’s 2026 earnings is pegged at $2.09 per share, indicating 71.3% year over year growth. PACS’s bottom line witnessed one upward revision in the past 30 days, with no movement in the opposite direction. The consensus estimate for 2026 revenues is pinned at $5.7 billion, calling for 7.7% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holding’s 2026 earnings is pegged at 75 cents per share, which has remained stable over the past 30 days. WGS beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for 2026 revenues is pinned at $545 million, implying 27.5% year-over-year growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Pediatrix Ties Up to Provide Better Maternal Care in Tennessee
Key Takeaways
Pediatrix Medical Group, Inc. (MD - Free Report) recently teamed up with Tennessee Maternal-Fetal Medicine, a specialist group focused on high-risk pregnancies and serving patients across five locations in the Greater Nashville area. The move is aimed at expanding the maternal health services suite of MD.
Following the deal, the practice will operate as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix network.
The transaction was completed in cash and is expected to be immediately accretive to Pediatrix’s bottom line. Financial details of the transaction were kept under wraps.
The addition of new providers and clinics is expected to drive higher patient volumes and support revenue growth for MD. Its same-unit net revenue increased 4% year over year in the fourth quarter of 2025. The expansion is likely to enhance its footprint in Tennessee, supporting stronger referral networks and more consistent patient inflow.
Such targeted expansions are expected to enable MD to capture the demand for specialized maternal care. Powered by four board-certified physicians along with six practice providers, Tennessee Maternal-Fetal Medicine seems to be an apt partner to complement MD’s endeavor, as the former’s professionals focus on complex pregnancies that require specialized monitoring and treatment.
MD’s Stock Price Performance
Shares of Pediatrix have gained 48.2% over the past year against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
MD’s Zacks Rank & Key Picks
Pediatrix currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Medical space are InnovAge Holding Corp. (INNV - Free Report) , PACS Group, Inc. (PACS - Free Report) and GeneDx Holdings Corp. (WGS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for InnovAge Holding’s 2026 earnings is pegged at 25 cents per share, which has remained stable in the past 30 days. INNV beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 87.5%. The consensus estimate for 2026 revenues is pinned at $944.5 million, implying 10.6% year-over-year growth.
The Zacks Consensus Estimate for PACS Group’s 2026 earnings is pegged at $2.09 per share, indicating 71.3% year over year growth. PACS’s bottom line witnessed one upward revision in the past 30 days, with no movement in the opposite direction. The consensus estimate for 2026 revenues is pinned at $5.7 billion, calling for 7.7% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holding’s 2026 earnings is pegged at 75 cents per share, which has remained stable over the past 30 days. WGS beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for 2026 revenues is pinned at $545 million, implying 27.5% year-over-year growth.